Clinical implications of the new biology in the development of melanoma vaccines
dc.contributor.author | Hemmila, Mark R. | en_US |
dc.contributor.author | Chang, Alfred E. | en_US |
dc.date.accessioned | 2006-04-19T13:38:16Z | |
dc.date.available | 2006-04-19T13:38:16Z | |
dc.date.issued | 1999-04 | en_US |
dc.identifier.citation | Hemmila, Mark R.; Chang, Alfred E. (1999)."Clinical implications of the new biology in the development of melanoma vaccines." Journal of Surgical Oncology 70(4): 263-274. <http://hdl.handle.net/2027.42/34523> | en_US |
dc.identifier.issn | 0022-4790 | en_US |
dc.identifier.issn | 1096-9098 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34523 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10219025&dopt=citation | en_US |
dc.description.abstract | There has been a resurgence in clinical research of vaccine therapies, particularly for the treatment of melanoma. The renewed interest in this field is attributable to an increased understanding regarding the immune response to tumors and the immunobiology of melanoma. Molecular biology techniques have enabled investigators to develop genetically engineered tumor vaccines that are intended to favor the type 1 immune response over the type 2 response. Melanoma-associated antigens have been characterized at the molecular level and are currently being investigated in clinical trials. Dendritic cell biology has also provided a potent method to present antigens to the host for immunization. Lastly, vaccines are being explored as a method to generate immune T-cells for adoptive immunotherapy. These new areas of clinical investigation will be reviewed in the context of the historical developments that have laid the foundations of this field. J. Surg. Oncol. 1999;70:263–274. © 1999 Wiley-Liss, Inc. | en_US |
dc.format.extent | 479369 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | John Wiley & Sons, Inc. | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Clinical implications of the new biology in the development of melanoma vaccines | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Surgery and Anesthesiology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Surgical Oncology, Department of Surgery, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Surgical Oncology, Department of Surgery, University of Michigan, Ann Arbor, Michigan ; 3302 University of Michigan Cancer Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109. | en_US |
dc.identifier.pmid | 10219025 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34523/1/14_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/(SICI)1096-9098(199904)70:4<263::AID-JSO14>3.0.CO;2-1 | en_US |
dc.identifier.source | Journal of Surgical Oncology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.